Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Aadi Bioscience, Inc. (ARPO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update"
05/10/2023 8-K Quarterly results
Docs: "Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial"
03/28/2023 8-K Quarterly results
11/09/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/17/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Aadi Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update"
11/10/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Aadi Reports Third Quarter 2021 Financial Results and Provides Business Update"
05/17/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : November 10, 2020 AERPIO PHARMACEUTICALS, INC. Delaware 001-38560 61-1547850 9987 Carver Road Cincinnati, OH 45242 Registrant's telephone number, including area code 985-1920 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-com...",
"Aerpio Reports Third Quarter 2020 Financial Results and Provides Business Update"
08/12/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/16/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "Employment Agreement, by and between the Company and Regina Marek",
"Aerpio Reports Third Quarter 2019 Financial Results and Provides Business Update CINCINNATI — — Aerpio Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today reported financial results for the third quarter ended September 30, 2019, and provided a business update. Recent Developments"
08/08/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : August 8, 2019 AERPIO PHARMACEUTICALS, INC. Delaware 001-38560 61-1547850 9987 Carver Road Cincinnati, OH 45242 Registrant's telephone number, including area code 985-1920 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commen...",
"Aerpio Reports Second Quarter 2019 Financial Results and Provides Business Update CINCINNATI—— Aerpio Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today reported financial results for the second quarter ended June 30, 2019, and provided a business update. “We remain committed to rapidly advancing our topical ocular formulation of AKB-9778 for primary open-angle glaucoma ,” said Stephen Hoffman, M.D., Ph.D., Chief Executive Officer of Aerpio. “Following the completion of our Phase 2b study in diabetic retinopathy, we took important steps to realign the Company. This realignment is designed to enable us to realize cost savings and efficiently utilize our resources as we direct our e..."
05/09/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : May 9, 2019 AERPIO PHARMACEUTICALS, INC. Delaware 001-38560 61-1547850 9987 Carver Road Cincinnati, OH 45242 Registrant's telephone number, including area code 985-1920 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencem...",
"Aerpio Reports First Quarter 2019 Financial Results and Provides Business Update"
03/05/2019 8-K Quarterly results
Docs: "FORM 8-K",
"Aerpio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update"
11/07/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : November 7, 2018 AERPIO PHARMACEUTICALS, INC. Delaware 001-38560 61-1547850 9987 Carver Road Cincinnati, OH 45242 Registrant's telephone number, including area code 985-1920 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-comm...",
"Aerpio Reports Third Quarter 2018 Financial Results and Provides Business Update"
08/14/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Aerpio Reports Second Quarter 2018 Financial Results and Provides Business Update"
03/13/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : March 13, 2018 AERPIO PHARMACEUTICALS, INC. Delaware 000-53057 61-1547850 9987 Carver Road Cincinnati, OH 45242 Registrant's telephone number, including area code 985-1920 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commen...",
"Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update"
05/16/2017 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy